COMMUNIQUÉS West-GlobeNewswire

-
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
18/03/2024 -
Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results
18/03/2024 -
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
18/03/2024 -
Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
18/03/2024 -
Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
18/03/2024 -
Madrigal Pharmaceuticals Announces Proposed Public Offering
18/03/2024 -
Carina Biotech to Present Three Poster Presentations at AACR Annual Meeting 2024
18/03/2024 -
Augmedix Delivers 45% Revenue Growth and Expanded Gross Margins for Fourth Quarter of 2023
18/03/2024 -
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
18/03/2024 -
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
18/03/2024 -
Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2
18/03/2024 -
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
18/03/2024 -
Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics Field
18/03/2024 -
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
18/03/2024 -
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
18/03/2024 -
TaiMed Biologics and AcedrA BioPharmaceuticals Partner to Commercialize Trogarzo® (Ibalizumab-uiyk) in the Middle East and North Africa Region
18/03/2024 -
Progyny, Inc. to Present at KeyBanc Life Sciences & MedTech Investor Forum
18/03/2024 -
RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit
18/03/2024 -
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21
18/03/2024
Pages